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Abstract 
 
Psychological disorders such as depression have more prevalence in inflammatory bowel disease patients 
and can exacerbate the clinical course of the disease, so anti-depressant therapy may have a potential to 
positively impact the disease course. On the other hand several antidepressant drugs have shown anti-
inflammatory and immunomodulatory properties. Thus, this study aimed to explore the beneficial effects of 
venlafaxine on experimental colitis in normal and reserpinised depressed rats. Acetic acid colitis was induced 
in both reserpinised and non-reserpinised rats. Reserpinised groups received reserpine at dose of 6 mg/kg 
i.p.1 h prior to colitis induction and then treated with venlafaxine at doses of 10, 20, 40 mg/kg given i.p. 2 h 
after induction of colitis and daily for 4 consecutive days. Non-reserpinised groups treated with 10, 20, 40 
mg/kg venlafaxine i.p. 2 h after the induction of colitis and daily for 4 successive days. Dexamethasone (1 
mg/kg, i.p.) was used as reference drug. Colonic inflammation was evaluated using macroscopic, histological 
and myeloperoxidase activity measurements. Results showed that reserpine at dose of 6 mg/kg exacerbated 
the colitis damage. Compared to acetic acid control, venlafaxine at dose of 40 mg/kg as well as 
dexamethasone significantly improved colitis parameters in both reserpinised and non-reserpinised animals. 
Venlafaxine reduced inflammatory injury in this animal model of induced ulcerative colitis. These effects are 
probably mediated first through depressive behavioral changes that could be mediated through the brain-gut 
axis and second for the anti-inflammatory effect of the drug. 
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INTRODUCTION 
 
Inflammatory bowel disease (IBD) 
including Crohn’s disease, and ulcerative 
colitis are considered as idiopathic diseases 
affecting the gastrointestinal tract (1). It is a 
chronic disease that has a high incidence in 
younger individual and lasts life-long (2). In 
clinical practice, disease activity is typically 
described as bloody diarrhea (often nocturnal 
and postprandial), passage of pus, mucus, or 
both, abdominal cramping, pain and fatigue 
which can present a significant challenge for 
daily functioning. Medical and surgical 
management has varying success, with up to 
half of IBD patients experiencing relapses 
every year (3). Although those with IBD have 
either little or no increased mortality risk relative 
to the general population, many patients have 
concerns regarding medication side effects, risk 
of cancer, and need for surgery. All of these 
aspects can contribute to psychological distress 
and undermine quality of life for those with IBD 
(4). The patients may feel frustrated, sad, and 
avoid social and sexual events. As a result, the 
illness may disrupt work, family and social life 
and predispose patient to anxiety and depression 
(5). Many review articles have now emphasized 
on the relationship between IBD and such 
psychological disorders (5-8).  
Depression and anxiety are more common in 
people with IBD than in the general population. 
More than 80% of IBD patients with            
active disease suffered from anxiety state             
and approximately 60% had concomitant 
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depression (9). These mental disorders have a 
high risk to occur during the first year after 
diagnosis of IBD (10). Presence of clinical 
depression may influence disease activity, 
aggravate disease symptoms, impact on the 
evolution of the disease (11) or the response to 
therapy (12).  
Recent studies have provided stronger 
evidence for plausible mechanisms by which 
psychological disorder effects could be 
transferred into gut inflammation, including 
changes in intestinal permeability and mucosal 
pro-inflammatory cytokines (5).  
Therefore, if psychological stress is indeed 
a pathogenic factor in IBD, then stress 
reduction therapy may have therapeutic 
benefit. Many researchers hypothesized that 
the course of IBD is influenced by 
psychological factors such as depression as it 
is influenced by somatic factors; so psychiatric 
treatment of patients improves both mental and 
somatic status of IBD patients (13-15).  
Milne and coworkers found that a stress 
management course in addition to 
conventional treatment significantly (P<0.05) 
reduced Crohn’s disease activity index over 
the follow up period of 1 year in a randomized 
trial of 80 patients with Crohn’s disease (16). 
Although a wide variety of anti-depressants 
are available but there are chiefly two classes 
of anti-depressants that besides treatment              
of depression have beneficial effect in 
nociceptive and inflammatory condition: 
tricyclic anti-depressant drugs (TCAs)                 
and serotonin-norepinephrine reuptake 
inhibitors (SNRIs) (17).  
Recently, the anti-inflammatory effects of 
some anti-depressants such as fluoxetine (18), 
amitriptyline (19), and maprotiline (20) have 
been reported in a number of experimental 
models of inflammation.  
Additionally, anti-nociceptive and anti-
inflammatory effects of venlafaxine were 
evaluated by Aricioglu and colleagues (21) in 
a rat model of inflammation.  
The aim of this study was therefore to 
evaluate the beneficial effects of venlafaxine, 
an antidepressant which inhibits reuptake               
of both serotonin and norepinephrine,                     
in experimental colitis in normal and 
reserpinised depressed rats.  
 
MATERIALS AND METHODS 
 
Chemicals 
Venlafaxine hydrochloride was a gift from 
Daroupakhsh Pharmaceutical Co. (Tehran, 
Iran). Dexamethasone was also a gift from 
Raha Pharmaceutical Co. (Isfahan, Iran). 
Reserpine, hexadecyl trimethyl-ammonium 
bromide (HTAB) and O-dianisidine 
dihydrochloride were purchased from Sigma 
Chemical Co. (St. Louis, Mo, USA). 
 Formalin solution 35% w/w, glacial acetic 
acid and diethyl ether oxide were supplied               
by Merck (Darmstadt, Germany). All                
other solvents and chemicals were of 
analytical grade. 
 
Animals 
Male Wistar rats weighing 200–250 g were 
obtained from the laboratory animal house of 
School of Pharmacy, Isfahan University of 
Medical Sciences and randomly distributed 
into several experimental groups.  
Animals were kept for a week prior to study 
so as to be adapted to the animal room 
conditions. The animal room was maintained 
at 22–24 °C and a lighting regimen of 12 h 
light/12 h dark. Rats were given standard 
pelleted chaw and having free access to water. 
All animal experiments were approved by the 
Ethics Committee of Isfahan University of 
Medical Science and performed in accordance 
with National Institute of Health Guide for the 
Care and Use of Laboratory Animals. 
 
Determination of anti-depressant dose of 
venlafaxine in reserpine treated rats 
In order to determine the effective anti-
depressant dose of venlafaxine in colitic rats, 
forced swimming test, which is a common 
behavioral test for assessing depressant and/or 
anti-depressant effect, was used. 
 To achieve this, 44 male Wistar rats were 
randomly assigned to 7 groups of 6 animals 
each as Sham, control and test groups as 
follows: 
Sham group: received daily i.p. injections 
of normal saline for 4 consecutive days. 
Control group: received reserpine (6 mg/kg, 
i.p.) on day one and daily injections of normal 
saline for next four days. 
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Test groups: received reserpine (6 mg/kg, 
i.p.) on day one and daily venlafaxine (5, 10, 
20, 40, 80 mg/kg, i.p.) for next four days.  
All doses were freshly prepared each 
morning.  
 
Forced swimming test in rats 
Forced swimming test (FST) was 
performed on two consecutive days according 
to Porsolt and coworkers (22). On the first day 
(the third day of the experiment) the rats were 
individually placed in cylinders containing 25 
°C water approximately 15 cm height for 15 
min. On the following day (day 4) the rats 
were again immersed in water and total 
duration of immobility was measured for 5 
min. The immobility time was regarded as the 
time spent by the rat floating in the water 
without struggling and making only those 
movements necessary to keep its head above 
water. 
 
Induction of experimental colitis 
All rats were fasted for 24 h before the 
induction of colitis but allowed free access to 
water. Colitis was induced according to the 
procedure described by the MacPherson and 
Pfeiffer (23). Briefly, animals were lightly 
anesthetized by ether, and colon was 
catheterized intra rectally, such that the tip 
advanced 8 cm proximal to the anus. Two ml 
of acetic acid (4% v/v in 0.9% saline) was 
slowly infused into the colon. Animals were 
then maintained in a head down position              
for 30 s to limit expulsion of the solution              
and returned. 
 
Animal grouping 
Rats were randomly divided into the 
following groups of six animals each: control 
group: received normal saline i.p. 2 h 
following induction of colitis; Sham group: 
cannulation was accomplished without 
induction of colitis (normal saline was 
administered instead of acetic acid), and            
rats also received normal saline i.p.; 
dexamethasone group: dexamethasone                   
(1 mg/kg, i.p) as a reference drug was given 2 
h following induction of colitis. Test groups 
included non-reserpine treated groups which 
received venlafaxine (10, 20, 40 mg/kg, i.p.) 2 
h following induction of colitis and reserpine-
treated groups which received reserpine (6 
mg/kg, i.p.), 1 h prior to induction of colitis 
and then treated with venlafaxine (10, 20, 40 
mg/kg, i.p.) 2 h following induction of colitis. 
Administration of medications was performed 
for the following four days. All drugs were 
administered in a volume equivalent to 1 ml 
/kg. All drug doses were calculated as mg/kg 
base, dissolved in normal saline and prepared 
freshly each morning.  
 
Evaluation of colon macroscopic damage 
On the day five, animals were sacrificed by 
means of ether inhalation. Immediately after, 
the abdomen was dissected open and the colon 
was removed and cut longitudinally, slightly 
cleaned in physiological saline to remove     
fecal residues and processed for macroscopic 
assessment, histological scores and 
biochemical marker (24).  
For each specimen, distal colon wet          
weight (g) (8 cm from the anus) was 
measured. Macroscopic damage scores were 
determined by an independent observer 
according to the following criteria: 0, no 
macroscopic changes; 1, mucosal erythema 
only; 2, mild mucosal edema, slight bleeding, 
or slight erosion; 3, moderate edema, bleeding 
ulcers, or erosions, and 4, severe ulceration, 
erosions, edema, and tissue necrosis (25).  
Then, tissue was fixed on a white plastic 
sheet and a photo was taken using an 
appropriately adjusted Nikon camera (Coolpix 
p100, Japan) to calculate the ulcer area. Then 
tissues were cut into two pieces, one piece for 
histopathology assessment (maintained in 5 ml 
formalin 10% as fixator) and the other for 
measuring myeloperoxidase (MPO) enzyme 
activity. The pieces for measuring MPO 
enzyme activity were frozen in liquid nitrogen 
and kept at -85 °C in a freezer until the day of 
analysis (26). 
Furthermore, ulcer area was measured by 
Fiji-win 32 software, an image processing and 
analysis software inspired by NIH Image for 
the Macintosh (27). For each specimen ulcer 
index was calculated using the following 
equation (28). 
Ulcer Index=Ulcer area (cm2) + Macroscopic score       (1) 
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Body weight measurement 
For each animal, body weight (g) was 
measured by a digital scale (ACCULAB V-
3000, Germany) daily and during the 
experimental period (prior to induction of 
colitis and subsequently daily for 5 days) (29). 
 
Myeloperoxidase enzyme activity measurement 
According to the modified method of 
Bradley and coworkers (30) each tissue sample 
(0.1 g) was chopped and in 1 ml of 50 mM 
potassium phosphate (pH=6) with 0.5% HTAB 
and 5 mM ethylenediaminetetraacetic acid in 
an ice bath using Polytron homogenizer 
(Brinkmann/Kinematica, USA). More buffers 
were added to obtain a concentration 
equivalent to 0.1 g of colon tissue per 5 ml 
medium. The resultant homogenate was 
sonicated in an ice bath for 10 s, then 
subjected to a sequence of freezing and 
thawing 3 times, and sonicated again for 10 s 
and centrifuged at 15,000 rpm for 15 min at    
4 °C. A 0.1 ml of the supernatant was mixed 
with 2.9 ml of 50 mM phosphate                       
buffer (pH=6) containing 0.167 mg/ml O-
dianisidine dihydrochloride and 0.0005% 
hydrogen peroxide. The change in the 
absorbance at 460 nm was measured using a 
UV/VIS spectrophotometer (LSI Model Alfa-
1502, China). 
 
Histological analysis 
Colon tissues were individually fixed in 
10% formalin, dehydrated, paraffin embedded, 
processed, sectioned in 4 μm thick slices, 
deparaffinized with xylene, hydrated and 
stained with hematoxylin and eosin (H&E) 
respectively (31).  
Inflammation severity and extent as well as 
crypt damage were evaluated on H&E-stained 
and coded using a validated scoring system as 
shown in Table 1 (32). Total colitis index was 
measured by summing three sub scores of 
inflammation severity, inflammation extent, 
and crypt damage (33).  
 
Statistical analysis 
The results were reported as mean ± SEM 
(standard error of mean) for parametric data 
and median (range) for non-parametric data. 
One-way analysis of variance (ANOVA) 
followed by Tukey as post hoc test was used to 
compare the parametric data; non-parametric 
data were analyzed using Mann-Whitney test. 
All statistical analyses were assessed using 
Graph Pad Prism 5 software. Minimum level 
of significance was considered at P<0.05. 
 
RESULTS 
 
Effect of venlafaxine on reserpinised 
depressed rat using forced swimming test 
Reserpine produced a significant increase in 
immobilization time as compared to Sham 
group (P<0.01).  
Treatment with venlafaxine at doses of 10, 
20, 40 and 80 mg/kg significantly (P<0.01, 
P<0.05, P<0.001 and P<0.01 respectively) 
decreased immobility time in reserpine-treated 
rats. However, there was no significant 
difference between venlafaxine at dose of 5 
mg/kg and reserpinised group in immobility 
time (Fig. 1). 
Table 1. Histological grading of colitis.  
Scoring parameter Score definition 
Inflammation severity 0 (None) 
 1 (Mild) 
 2 (Moderate) 
 3 (Severe) 
  
Inflammation extent 0 (None) 
 1 (Mucosa) 
 2. (Mucosa  and submucosa) 
 3 (Transmural) 
  
Crypt damage 0 (None) 
 1 (Basal 1/3 damaged) 
 2 (Basal 2/3 damaged) 
 3 (Crypts lost, surface epithelium present) 
 4 (Crypts lost, surface epithelium lost) 
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Fig. 1. Effect of venlafaxine (5, 10, 20, 40, 80 mg/kg, i.p.) on duration of immobility (s) during forced swimming test in 
reserpinised (6 mg/kg, i.p.) rats, Res; reserpine (6 mg/kg), i.p.; intraperitoneally. Results are expressed as mean ± S.E.M 
of 6 rats in each group. *P<0.05, **P<0.01 and ***P<0.001 compared to Res. ##P<0.01 compared to Sham; one-way 
ANOVA followed by Tukey test. 
 
 
 
 
Fig. 2. Effect of venlafaxine (Ven, 10, 20, 40 mg/kg, i.p.) on body weight changes (g) in rat with acetic acid-induced 
colitis. Treatments were administered 2 h after acetic acid instillation and daily thereafter for 4 consecutive days. A; 
normal rats, B; reserpinised (6 mg/kg, i.p.) depressed rats, i.p.; intraperitoneally, Dex.1; dexamethasone (1 mg/kg), Res; 
reserpine (6 mg/kg), Ven; venlafaxine. Results are expressed as mean ± S.E.M of 6 rats in each group. *P<0.05, 
**P<0.01 and ***P<0.001 compared to control. #P<0.05, ##P<0.01 and ###P<0.001 compared to Sham; one-way 
ANOVA followed by Tukey test. 
 
    
Fig. 3. Effect of venlafaxine (10, 20, 40 mg/kg, i.p.) on ulcer index. A; normal rats, B; reserpinised (6 mg/kg, i.p.) 
depressed rats, i.p.; intraperitoneally, Dex.1; dexamethasone (1 mg/kg), Res; reserpine (6 mg/kg). Results are expressed 
as mean ± S.E.M of 6 rats ineach group. *P<0.05, **P<0.01 and ***P<0.001 compared to control. ###P<0.001 
compared to Sham; one-way ANOVA followed by Tukey test. 
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Assessment of animal body weights 
As it is shown in Figs. 2 and 3, acetic acid-
induced colitis led to a gradual decrease in 
body weight as observed in control group from 
day two till day five. In non-reserpinised rats, 
treatment with venlafaxine at 40 mg/kg dose 
from day four till day five showed a significant 
improvement of the wasting disease compared 
to rats treated with acetic acid alone (P<0.05). 
Rats treated with dexamethasone (1 mg/kg, 
i.p.) also showed a decrease in body weight 
loss in day five (P<0.05). In reserpinised rats, 
treatment with venlafaxine (40 mg/kg, i.p.) for 
five days reversed the decrease trend in body 
weight in day five which was comparable with 
dexamethasone (1 mg/kg) treated rats. 
Significant decrease in body weight was 
observed in reserpine group (6 mg/kg, i.p.) as 
compared with Sham group. 
 
Effect of venlafaxine on macroscopic 
features 
Two parameters including ulcer index and 
weight of distal colon were used to evaluate 
the effect of venlafaxine on macroscopic 
features. Five days after induction of colitis, 
acetic-acid control and reserpine (6 mg/kg) 
groups experienced severe inflammation, 
hemorrhage, ulcer, necrosis, and thickened 
colon wall, while the normal macroscopic 
features were evident in colons of Sham group 
(Fig. 4). Administration of reserpine (6 mg/kg, 
i.p.) intensified epithelial necrosis and edema 
so that ulcer index and weight of colon 
significantly increased (Fig. 3B, 5B and 4c). 
Administration of acetic acid in the colon 
caused a significant increase in the colon 
weight suggesting marked inflammation and 
edema as compared to Sham (Fig. 5). 
 
Fig. 4. Macroscopic presentation of colonic tissue 5 days after colitis induction in rats. a; normal colon, b; acetic acid-
control rat, c; reserpinised (6 mg/kg, i.p.) colitic rat, d; treatment with dexamethasone (1 mg/kg, i.p.) in colitic rat, e and 
f; treatment with venlafaxine (20, 40 mg/kg, i.p.) in colitic rats, g and h; treatment with venlafaxine (20, 40 mg/kg, i.p.) 
in reserpinised (6 mg/kg, i.p.) colitic rats. 
 
 
 
Fig. 5. Effect of venlafaxine (10, 20, 40 mg/kg, i.p.) on the weight of distal colon. A; normal rats, B; reserpinised (6 
mg/kg, i.p.) depressed rats, i.p; intraperitoneally, Dex.1; dexamethasone (1 mg/kg), Res; reserpine (6 mg/kg). Results 
are expressed as mean ± S.E.M of 6 rats in each group.*P<0.05, **P<0.01 and ***P<0.001 compared to control. 
###P<0.001 compared to Sham; one-way ANOVA followed by Tukey test. 
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As illustrated in Figs. 3, 4 and 5, 
dexamethasone (1 mg/kg, i.p.) as the reference 
drug improved macroscopic scores and thus 
both ulcer index and weight of distal colon 
was attenuated. In non-reserpinised rats, 
treatment with venlafaxine at doses of 20 and 
40 mg/kg significantly attenuated both ulcer 
index and weight of distal colon (Fig. 3A, 4a). 
Besides in reserpinised depressed rats, 
venlafaxine at dose of 40 mg/kg significantly 
(P<0.01) attenuated weight of distal colon 
(Figs. 5B, 4h). 
Induction of colitis caused a significant 
increase in the colon weight (P<0.001). A 
significant reduction in the colon weight was 
observed in the rats treated with venlafaxine at 
doses of 20 mg/kg (P<0.05), 40 mg/kg 
(P<0.01) in non-reserpinised animals and 40 
mg/kg (P<0.01) in reserpinised depressed 
animals. Treatment with dexamethasone               
(1 mg/kg, i.p.) also attenuated the weight of 
distal colon significantly (P<0.01) in both 
reserpinised and non-reserpinised groups. 
 
Effect of venlafaxine on myeloperoxidase 
activity 
As it is shown in Fig. 6 colonic MPO 
activity increased in control acetic acid and 
reserpine group and it shows that following 
induction of colitis, polymorphonuclear 
neutrophils accumulation in the colon tissue 
markedly increased. Treatment of rats with 
venlafaxine at doses of 40 mg/kg attenuated 
MPO activity level in both reserpinised and 
non-reserpinised colitic rats (Fig. 6). 
Administration of dexamethasone (1 mg/kg, 
i.p.) also produced a significant reduction in 
MPO levels. 
 
Effect of venlafaxine on histopathological 
features 
Intracolonic administration of acetic acid 
resulted in edema, loss of mucosal architecture 
with ulceration, necrosis and acute 
inflammatory cell infiltration to mucus and 
sub-mucosal layers (Fig. 7b). Administration 
of reserpine (6 mg/kg, i.p.) caused 
exacerbation of colonic damage so that median 
total colitis index increased as compared to 
control group (Table 2). As shown in Fig. 7a, 
Sham group exhibited a normal architecture 
with intact epithelium in colonic mucosa. 
Treatment with dexamethasone (1 mg/kg, i.p.) 
attenuated the inflammation severity and 
extent as well as crypt damage and total colitis 
index in injurious colons (Table 2). 
Venlafaxine at dose of 40 mg/kg significantly 
decreased the inflammatory parameters in both 
reserpinised (6 mg/kg, i.p.) and non-
reserpinised rats (Fig. 2).  
In non-reserpinised rats, i.p. administration 
of venlafaxine at 20 mg/kg reduced crypt 
damage as compared to control acetic acid 
group (Table 2).  
 
 
  
Fig. 6. Effect of venlafaxine (10, 20, 40 mg/kg, i.p.) on myeloperoxidase enzyme activity in the colonic tissue. A; 
normal rats, B; reserpinised (6 mg/kg, i.p.) depressed rats, i.p. intraperitoneally, Dex.1; dexamethasone (1 mg/kg), Res; 
reserpine (6 mg/kg). Results are expressed as mean ± S.E.M of 6 rats in each group. *P<0.05, **P<0.01 and 
***P<0.001 compared to control. ##P<0.01 and ###P<0.001 compared to Sham; one-way ANOVA followed by Tukey 
test.  
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Fig. 7. pathologic presentation of rat colonic tissue following five days treatment. a; Sham group showing intact 
epithelial surface, b; acetic acid control group showing gross damage to mucosal layer with crypt damage, c; treatment 
with reserpine (6 mg/kg, i.p.) in reserpine group showing severe damage to mucosal and submucosal layers with crypt 
damage, d; treatment with dexamethasone (1 mg/kg, i.p.) in dex. 1 group showing improved colonic damage with 
moderate inflammation, e and f; treatment with venlafaxine (40 mg/kg) in non-reserpinised and reserpinised (6 mg/kg, 
i.p.) groups respectively showing moderate destruction of mucosal layer however healing effect and repairing in 
mucosal layer is also evident; H&E staining with magnification of 10x, i.p.; intraperitoneally. 
 
 
Table 2. Effect of venlafaxine (Ven, 10, 20, 40 mg/kg, i.p.) on pathologic parameters of colitis induced by acetic acid 
in normal and reserpinised (6 mg/kg, i.p.) depressed rats. 
Groups Inflammation severity (0-3) 
Inflammation extent 
(0-3) 
Crypt damage 
(0-4) 
Total colitis index 
(0-10) 
Sham 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Control 3 (2-3) 2 (2-3) 4 (1-4) 9.5 (6-10) 
Dex. 1 0.5 (0-1)** 0 (0-2)** 0 (0-2)** 1 (0-5)** 
Ven. 10 2 (1-3) 3 (1-3) 3 (2-4) 7.5 (6-10) 
Ven. 20 1.5 (0-3) 2.5 (0-3) 1.5 (0-3)* 7.5 (0-9) 
Ven. 40 1 (0-3)* 1.5 (0-3)* 0 (0-3)** 3.5 (0-8)** 
Res 3 (1-3) 3 (1-3) 4 (1-4) 10 (4-10) 
Res + Ven. 10 2.5 (2-3) 3 (1-3) 3 (2-4) 8 (6-10) 
Res + Ven. 20 2 (1-3) 3 (1-3) 2 (1-4) 6.5 (4-9) 
Res + Ven. 40 1 (0-2)** 1 (0-2)** 0.5 (0-2)* 2 (0-7)** 
Dex.1; dexamethasone (1 mg/kg), Res; reserpine (6 mg/kg), i.p.; intraperitoneally. Values are presented as median 
(range) of six rats in each group. *P<0.05, **P<0.01 compared to control, Mann-Whitney test. 
 
DISCUSSION 
 
Some researchers have proposed that 
prevalence of psychological disorders 
especially depression and anxiety is higher in 
patients with IBD particularly within the first 
year of diagnosis (10). These psychological 
disorders may impact on the clinical course of 
disease, have the potential to exacerbate 
disease activity and may disturb the 
mainstream treatment of IBD disease (33).  
There is a bidirectional interaction between 
the gut and the brain through the autonomic 
nervous system and the circumventricular 
organs in physiological and pathological 
conditions called brain-gut axis (34). 
Environmental signals, such as stress or 
depressive symptoms, are perceived initially 
by the central nervous system (CNS). Signals 
are transmitted through this innervated plexus 
to the gut, and become involved in the 
initiation and relapse of experimental colitis 
(35). Despite the absence of any firm evidence 
to support this belief, Kurina and colleagues 
reported that in patients with IBD, depression 
and anxiety, should be thoroughly screened 
and would benefit from psychological 
treatment (10). For the first time, in the current 
study, we used a set of animal models to 
evaluate the role of venlafaxine on the 
experimental colitis in normal and reserpinised 
depressed rats. In this regard, before starting 
the experimental model of colitis, we 
conducted behavioral tests to discover the 
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appropriate antidepressant dose of venlafaxine 
to figure out if the beneficial effect of 
venlafaxine is mediated either through change 
in behavioral mood through the brain-gut axis 
or through its inherent anti-inflammatory 
effect. 
Intraperitoneal administration of reserpine 
in an excess dose depletes monoamine levels 
in the brain for more than a week and induces 
depressive behavior (36,37). The decrease in 
monoamine levels induced by reserpine 
permits the use of animal model of depression 
induced by this agent as a screening tool for 
the study of the antidepressant effect of 
venlafaxine. Intraperitoneal administration of a 
single dose of reserpine (10 mg/kg, i.p.) 
successfully induced depression which 
persisted for more than a week and treatment 
of the depressed animals for nine days reduced 
the sign of depression behavior (38). 
Furthermore, in a recent study, depression was 
induced by the administration of a single dose 
of reserpine and depression behavior and anti-
depressant effect was evaluated using FST 
(39). In accordance with above mentioned 
studies, reserpine at dose of 6 mg/kg was 
administered i.p. to induce depression during 
the period that anti-colitis and anti-depressant 
effect of venlafaxine was evaluated by forced 
swimming test. FST is also the most widely 
used technique to assess antidepressant effects 
in small rodents. Most of the clinically active 
antidepressants are active in the forced swim 
test (40,41). Rénéric and Lucki demonstrated 
that anti-depressant effect of venlafaxine at 
doses of 10, 20, 40 and 80 mg/kg dose-
dependently reduced immobility and increased 
swimming behavior in the FST (42). Our 
results also showed that venlafaxine at doses 
of 10, 20, 40 and 80 mg/kg reduced the 
immobility time induced by i.p. injection of 
reserpine (Fig. 1). However, only 10, 20 and 
40 mg/kg of venlafaxine were used in the 
ulcerative colitis experiments.  
Acetic acid-induced colitis is a rapid and 
reproducible model of colitis for screening of 
drugs with anti-colitic activity. This model has 
similarity to pathological and clinical features 
of the human ulcerative colitis (43,44). The 
results of the current study indicated that 
following five days treatment, venlafaxine 
improved colonic macroscopic and 
histological damages in both normal and 
reserpinised depressed rats. Twenty four hours 
after induction of colitis animal showed 
colonic hemorrhage and bloody stools with 
malnutrition which caused weight loss during 
the five days of experiment. Treatment of 
animals with venlafaxine at dose of 40 mg/kg 
improved body weight loss from day four as 
seen with reference group received 
dexamethasone at 1 mg/kg. Venlafaxine also 
at dose of 40 mg/kg corrected the elevated 
amount of biochemical marker MPO. 
Following induction of colitis, infiltration of 
neutrophils and other immune cells increased 
in the inflamed tissues that caused an increase 
in MPO activity enzyme level in the tissue 
(45). In the preset study, MPO activity was 
conspicuously enhanced in control rats and did 
not show any significant difference with 
control group receiving reserpine at dose of 6 
mg/kg.  
It has been reported that antidepressants 
increase intracellular concentration of cAMP 
in immune cells through activation of 
noradrenaline and serotonin receptors (46). 
This may be one of the mechanisms by which 
venlafaxine at the mentioned dose alleviated 
inflammation in the experimental colitis. 
However, little attention has been paid to 
the role of depression in predisposition to 
inflammatory conditions of the gastrointestinal 
tract. In this study, we used reserpine induced 
depression model to show increased 
susceptibility to the experimental colitis in 
which this vulnerability could be reduced by 
antidepressant therapy. Administration of the 
reserpine as depressing agent; at dose of 6 
mg/kg conversely exacerbate the colitis 
condition as indicated in macroscopic, 
histological and MPO measurements. 
Induction of depression in animal models such 
as maternal separation in mice increases 
vulnerability to intestinal inflammation. It is 
hypothesized that increased intestinal 
permeability facilitate the enhanced severity of 
subsequent dextran sulphate sodium colitis 
which is reversed by treatment with tricyclic 
antidepressant desipramine (47). In the present 
study induction of depression by 
administration of reserpine (Fig. 1) 
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exacerbated the colitis damage while treatment 
with venlafaxine attenuated the increased 
susceptibility to colitis in reserpinised 
depressed rats.  
Mast cells of the intestinal mucosa serve as 
end effectors of the brain-gut axis and release 
several pro-inflammatory mediators following 
stress and other psychological disorders that 
can profoundly affect GI physiology by 
inducing intestinal hyperpermeability and 
activation of mucosal immune function (34). 
Reserpinised treated rat with the anti-
depressant venlafaxine showed decreased 
colitis severity as compared with untreated 
reserpine group. Thus treatment of these 
psychological disorders by anti-depressant 
venlafaxine can modulate the function of these 
immune cells and reduce intestinal 
inflammation. 
Furthermore, experimental evidence is 
accumulating that various types of 
antidepressants (particularly TCAs and SNRIs) 
exert anti-inflammatory and analgesic effects. 
Anti-inflammatory and analgesic effects of 
venlafaxine have been also reported in some 
studies. Anti-nociceptive effect of venlafaxine 
on painful peripheral diabetic neuropathy, 
fibromyalgia and headache has been evaluated 
in clinical studies. Anti-nociceptive effect of 
venlafaxine at doses of 10 and 22.5 mg/kg in 
mice (tail flick and writhing tests) has been 
reported and it is realized that this effect could 
possibly have central as well as peripheral 
action (48). Anti-inflammatory effect of 
venlafaxine in carrageenan-induced paw 
edema in rats has also been reported (21). 
Since colitis is an inflammatory condition                         
of intestine, it is deduced from our results that 
some beneficial effect of venlafaxine                      
in experimental colitis might be, in part,               
due to its anti-inflammatory and anti-
nociceptive effects. 
 
CONCLUSION 
 
The results of this investigation showed 
anti-inflammatory effect of the anti-
depressant, venlafaxine in acetic acid-induced 
colitis. Our results confirmed that a coherent 
communication exist between depression and 
the course of IBD probably through the brain-
gut axis. This correlation was previously 
approved in irritable bowel syndrome, the 
issue which has historical background when 
IBD was considered as a psychosomatic 
disease. Further studies are suggested to 
evaluate other anti-depressant drugs with 
similar pharmacological properties in the 
treatment of ulcerative colitis. 
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